NL300779I2 - Combinatie van a) olodaterol, het individuele optische R-isomeer daarvan, mengsels van individuele enantiomeren of racematen, zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, desgewenst in de vorm van solvaten en/of hydraten, en b) een tiotropiumzout; in het bijzonder combinatie van a) olodaterol en zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, en b) tiotropiumbromide, desgewenst in de vorm van een solvaat en/of hydraat; meer in het bijzonder combinatie van a) olodaterolhydrochloride en b) tiotropiumbromide, desgewenst in de vorm van het monohydraat - Google Patents

Combinatie van a) olodaterol, het individuele optische R-isomeer daarvan, mengsels van individuele enantiomeren of racematen, zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, desgewenst in de vorm van solvaten en/of hydraten, en b) een tiotropiumzout; in het bijzonder combinatie van a) olodaterol en zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, en b) tiotropiumbromide, desgewenst in de vorm van een solvaat en/of hydraat; meer in het bijzonder combinatie van a) olodaterolhydrochloride en b) tiotropiumbromide, desgewenst in de vorm van het monohydraat

Info

Publication number
NL300779I2
NL300779I2 NL300779C NL300779C NL300779I2 NL 300779 I2 NL300779 I2 NL 300779I2 NL 300779 C NL300779 C NL 300779C NL 300779 C NL300779 C NL 300779C NL 300779 I2 NL300779 I2 NL 300779I2
Authority
NL
Netherlands
Prior art keywords
optionally
olodaterol
combination
acid addition
addition salts
Prior art date
Application number
NL300779C
Other languages
English (en)
Dutch (nl)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300779(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102004019540A external-priority patent/DE102004019540A1/de
Priority claimed from DE102004052987A external-priority patent/DE102004052987A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NL300779I2 publication Critical patent/NL300779I2/nl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NL300779C 2004-04-22 2015-12-01 Combinatie van a) olodaterol, het individuele optische R-isomeer daarvan, mengsels van individuele enantiomeren of racematen, zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, desgewenst in de vorm van solvaten en/of hydraten, en b) een tiotropiumzout; in het bijzonder combinatie van a) olodaterol en zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, en b) tiotropiumbromide, desgewenst in de vorm van een solvaat en/of hydraat; meer in het bijzonder combinatie van a) olodaterolhydrochloride en b) tiotropiumbromide, desgewenst in de vorm van het monohydraat NL300779I2 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102004019540A DE102004019540A1 (de) 2004-04-22 2004-04-22 Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
DE102004052987A DE102004052987A1 (de) 2004-11-03 2004-11-03 Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
EP05002496 2005-02-07
PCT/EP2005/004073 WO2005102349A1 (de) 2004-04-22 2005-04-18 Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
EP05739576A EP1781298B1 (de) 2004-04-22 2005-04-18 Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen

Publications (1)

Publication Number Publication Date
NL300779I2 true NL300779I2 (nl) 2017-11-02

Family

ID=34966478

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300779C NL300779I2 (nl) 2004-04-22 2015-12-01 Combinatie van a) olodaterol, het individuele optische R-isomeer daarvan, mengsels van individuele enantiomeren of racematen, zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, desgewenst in de vorm van solvaten en/of hydraten, en b) een tiotropiumzout; in het bijzonder combinatie van a) olodaterol en zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, en b) tiotropiumbromide, desgewenst in de vorm van een solvaat en/of hydraat; meer in het bijzonder combinatie van a) olodaterolhydrochloride en b) tiotropiumbromide, desgewenst in de vorm van het monohydraat

Country Status (33)

Country Link
EP (2) EP1781298B1 (enExample)
JP (1) JP2007533683A (enExample)
KR (2) KR101287460B1 (enExample)
AR (1) AR049262A1 (enExample)
AT (1) ATE539754T1 (enExample)
AU (1) AU2005235419B2 (enExample)
BE (1) BE2015C065I2 (enExample)
BR (1) BRPI0510080B8 (enExample)
CA (1) CA2559699C (enExample)
CY (3) CY1113890T1 (enExample)
DK (2) DK2422786T3 (enExample)
EA (1) EA013157B1 (enExample)
EC (1) ECSP066947A (enExample)
ES (2) ES2523518T3 (enExample)
FI (1) FIC20170005I1 (enExample)
FR (1) FR16C0029I2 (enExample)
HU (1) HUS1500058I1 (enExample)
IL (2) IL177685A (enExample)
LT (1) LTC1781298I2 (enExample)
LU (1) LU93066I2 (enExample)
MY (1) MY148945A (enExample)
NL (1) NL300779I2 (enExample)
NO (2) NO337714B1 (enExample)
NZ (1) NZ550797A (enExample)
PE (1) PE20060462A1 (enExample)
PL (2) PL1781298T4 (enExample)
PT (2) PT2422786E (enExample)
SG (1) SG152237A1 (enExample)
SI (2) SI1781298T1 (enExample)
TW (2) TWI374739B (enExample)
UY (1) UY28861A1 (enExample)
WO (1) WO2005102349A1 (enExample)
ZA (1) ZA200606624B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US7923455B2 (en) * 2005-01-28 2011-04-12 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
EP1855689A1 (en) * 2005-02-16 2007-11-21 Boehringer Ingelheim International GmbH Pharmaceutical compositions comprising anticholinergics and etiprednol
BRPI0614410A2 (pt) 2005-08-15 2011-03-29 Boehringer Ingelheim Int processo para preparação de betamiméticos
US20070088030A1 (en) 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
US20070086957A1 (en) 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
ATE529399T1 (de) * 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
EP1986644A1 (de) * 2006-02-16 2008-11-05 Boehringer Ingelheim International GmbH Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
CA2660186A1 (en) * 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of respiratory diseases
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
US20100099651A1 (en) * 2006-10-26 2010-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
JP2012509922A (ja) * 2008-11-27 2012-04-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規粉末化結晶質吸入薬
WO2014016548A2 (en) * 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
WO2014056840A1 (en) 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Beta-2-adrenoceptor agonist for the treatment of cough

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
SK15382002A3 (sk) * 2000-04-27 2003-03-04 Boehringer Ingelheim Pharma Kg Betamimetiká, farmaceutický prostriedok s ich obsahom a ich použitie
WO2002030928A1 (de) 2000-10-12 2002-04-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kristallines monohydrat, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
ME00412B (me) 2001-06-22 2011-10-10 Boehringer Ingelheim Pharma Kristalni antiholinergik , postupak za njegovo pripremanje i njegova primjena u proizvodnji lijeka
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
DE10230751A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern
DE10246374A1 (de) * 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Also Published As

Publication number Publication date
UY28861A1 (es) 2005-11-30
PT1781298E (pt) 2012-02-03
EA200601846A1 (ru) 2007-04-27
TW201231055A (en) 2012-08-01
DK2422786T3 (da) 2014-11-17
FR16C0029I2 (fr) 2017-01-27
PL2422786T3 (pl) 2015-02-27
LTC1781298I2 (lt) 2018-09-25
CA2559699A1 (en) 2005-11-03
NZ550797A (en) 2010-08-27
IL226562A0 (en) 2013-06-27
ES2380370T3 (es) 2012-05-11
FIC20170005I1 (fi) 2017-01-13
FR16C0029I1 (enExample) 2016-08-26
AR049262A1 (es) 2006-07-12
IL177685A0 (en) 2006-12-31
BRPI0510080A (pt) 2007-10-16
SI1781298T1 (sl) 2012-04-30
MY148945A (en) 2013-06-14
CY1113890T1 (el) 2016-07-27
EP1781298B1 (de) 2012-01-04
EP2422786A1 (de) 2012-02-29
NO2016022I2 (no) 2016-12-01
LU93066I2 (fr) 2016-07-11
HUS1500058I1 (hu) 2016-01-28
BE2015C065I2 (enExample) 2024-08-08
PL1781298T3 (pl) 2012-06-29
WO2005102349A1 (de) 2005-11-03
DK1781298T3 (da) 2012-05-07
IL177685A (en) 2013-10-31
BRPI0510080B1 (pt) 2020-08-18
EP1781298A1 (de) 2007-05-09
NO2016022I1 (no) 2016-12-01
AU2005235419A1 (en) 2005-11-03
BRPI0510080B8 (pt) 2021-05-25
CY1115719T1 (el) 2017-01-25
ATE539754T1 (de) 2012-01-15
ECSP066947A (es) 2007-01-26
ES2523518T3 (es) 2014-11-26
CY2017014I2 (el) 2017-11-14
CA2559699C (en) 2012-06-19
PE20060462A1 (es) 2006-06-19
SG152237A1 (en) 2009-05-29
KR101287460B1 (ko) 2013-07-23
ZA200606624B (en) 2008-01-08
NO337714B1 (no) 2016-06-06
EP2422786B1 (de) 2014-08-13
TWI372056B (en) 2012-09-11
JP2007533683A (ja) 2007-11-22
KR20130049840A (ko) 2013-05-14
PT2422786E (pt) 2014-11-12
TWI374739B (en) 2012-10-21
SI2422786T1 (sl) 2014-12-31
KR20070015592A (ko) 2007-02-05
PL1781298T4 (pl) 2017-07-31
NO20065060L (no) 2006-11-21
EA013157B1 (ru) 2010-02-26
AU2005235419B2 (en) 2010-11-04
CY2017014I1 (el) 2017-11-14

Similar Documents

Publication Publication Date Title
NL300779I2 (nl) Combinatie van a) olodaterol, het individuele optische R-isomeer daarvan, mengsels van individuele enantiomeren of racematen, zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, desgewenst in de vorm van solvaten en/of hydraten, en b) een tiotropiumzout; in het bijzonder combinatie van a) olodaterol en zuuradditiezouten daarvan met farmacologisch aanvaardbare zuren, en b) tiotropiumbromide, desgewenst in de vorm van een solvaat en/of hydraat; meer in het bijzonder combinatie van a) olodaterolhydrochloride en b) tiotropiumbromide, desgewenst in de vorm van het monohydraat
NL301104I1 (nl) Fedratinib, of een farmaceutisch aanvaardbaar zout daarvan, of een farmaceutisch aanvaardbaar hydraat daarvan, in het bijzonder fedratinibdihydrochloridemonohydraat
NO2022022I1 (no) Fedratinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, in particular fedratinib dihydrochloride monohydrate
NL301199I2 (nl) Difelikefalin, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, hydraat, solvaat, zuurzout-hydraat of N-oxide
NL301106I1 (nl) Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NO2017010I2 (no) Dolutegravir eller et farmasøytisk akseptabelt salt eller solvat derav
NL301150I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301042I2 (nl) Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301004I2 (nl) Dacomitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL300865I2 (nl) Eluxadoline of een farmaceutisch aanvaardbaar zout ervan
NL301067I2 (nl) Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL300993I2 (nl) Apalutamide of een farmaceutisch aanvaardbaar zout daarvan
DK1711481T4 (da) Krystallinsk monohydrat som kinaseinhibitorer
NO2017051I1 (no) Kariprazin, eventuelt i form av et salt, inkludert kariprazin hydroklorid
DE602006018355D1 (de) Transdermale verabreichung eines meptazinolsalzes
NO2013008I1 (no) Krizotinib eller et farmasøytisk akseptabelt salt,hydrat eller solvat derav
NL300937I2 (nl) Niraparib, of een tautomeer daarvan, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder het tosylaat of een hydraat, meer in het bijzonder het tosylaat monohydraat
PL1931645T3 (pl) Pochodne N-(3-amino-chinoksalin-2-ylo)-sulfonamidu i ich zastosowanie jako inhibitorów kinazy-3 fosfatydyloinozytolu
SMP201000002B (it) Sali dell'inibitore di chinasi janus (R)-3-(4-(7H-pirrolo[2,3-D]pirimidin-4-IL)-1H-pirazoli-1-IL)-3-ciclopentilpropanonitrile
DE60330909D1 (de) Tablette mit modifizierter freisetzung von bupropion hydrochlorid
AR061980A1 (es) Acilanilidas sustituidas y metodos para su utilizacion
ME02688B (me) Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta
TW200716567A (en) Aspartyl protease inhibitors
DK1789021T4 (da) Forlænget-frigivelse-tabletformulering indeholdende pramipexol eller et farmaceutisk acceptabelt salt deraf
PE20080559A1 (es) Derivados de heteroaril sustituidos